Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)

Autor: Magdalena Mileva, Elisabeth G. E. de Vries, Thomas Guiot, Zéna Wimana, Anne-Leen Deleu, Carolien P. Schröder, Yolene Lefebvre, Marianne Paesmans, Sigrid Stroobants, Manon Huizing, Philippe Aftimos, Jolien Tol, Winette T. A. Van der Graaf, Wim J. G. Oyen, Danielle J. Vugts, C. Willemien Menke-van der Houven van Oordt, Adrienne H. Brouwers, Martine Piccart-Gebhart, Patrick Flamen, Géraldine Gebhart

Publikováno v: npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)

Abstract Efficacy of the human epidermal growth factor receptor (HER)2-targeting trastuzumab emtansine (T-DM1) in breast cancer (BC) relies on HER2 status determined by immunohistochemistry or fluorescence in-situ hybridization. Heterogeneity in HER2

Externí odkaz: https://doaj.org/article/b8159ecb1674471b9a212c77843626e6

HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study

Autor: Altuna Halilovic, Dagmar I. Verweij, Annet Simons, Marian J. P. L. Stevens-Kroef, Susan Vermeulen, Janet Elsink, Bastiaan B. J. Tops, Irene Otte-Höller, Jeroen A. W. M. van der Laak, Carlijn van de Water, Oliver B. A. Boelens, Margrethe S. Schlooz-Vries, Jeroen R. Dijkstra, Iris D. Nagtegaal, Jolien Tol, Patricia H. J. van Cleef, Paul N. Span, Peter Bult

Publikováno v: Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)

Abstract Breast cancer treatment depends on human epidermal growth factor receptor-2 (HER2) status, which is often determined using dual probe fluorescence in situ hybridisation (FISH). Hereby, also loss and gain of the centromere of chromosome 17 (C

Externí odkaz: https://doaj.org/article/eccb0d74ba084146a4c3d5d34a19dea5

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry

Autor: Khava I. E. Ibragimova, Sandra M. E. Geurts, Marissa Meegdes, Frans Erdkamp, Joan B. Heijns, Jolien Tol, Birgit E. P. J. Vriens, Marcus W. Dercksen, Kirsten N. A. Aaldering, Manon J. A. E. Pepels, Linda van de Winkel, Natascha A. J. B. Peters, Nathalie J. A. Teeuwen-Dedroog, Ingeborg J. H. Vriens, Vivianne C. G. Tjan-Heijnen

Publikováno v: Breast Cancer Research and Treatment, 198(2), 239-251. Springer, Cham

Purpose We assessed the systemic treatment choices and outcomes in patients diagnosed with human epidermal growth factor receptor-2-positive (HER2 +) advanced breast cancer (ABC), for the first four lines of systemic therapy and by hormone receptor (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::091519dce89e341c24a7da6466f819d5
https://doi.org/10.1007/s10549-022-06832-9

Supplementary Figure S1 from Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Autor: Annemieke Cats, Jan H.M. Schellens, Cornelis J.A. Punt, Jos H. Beijnen, Paul H.M. Smits, Henk-Jan Guchelaar, Andrew Vincent, Anthonius de Boer, Valerie D. Doodeman, Artur M Burylo, Jolien Tol, Maarten J. Deenen

Supplementary Figure S1.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bca2b87f674d91b3e5d17cedc2bf202
https://doi.org/10.1158/1078-0432.22440949

Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Autor: F. Terhegggen, G. P. Bootsma, Hans M. Westgeest, Jessica S.W. Borgers, Daphne W. Dumoulin, M. Cloos, J. W. G. van Putten, John B. A. G. Haanen, C. J. van Loenhout, W. K. de Jong, I. Houtenbos, G. A. Cirkel, Otto Visser, J. C. Drooger, R. A.W. van de Wetering, T. J.N. Hiltermann, B. van den Borne, F. S. van der Meer, V. J.A.A. Nuij, Esther Oomen-de Hoop, C. H. van der Leest, Hanneke W. M. van Laarhoven, A. Becker-Commissaris, S. C.van t. Westeinde, A. P. Hamberg, L. van Leeuwen, A. S.R. van Lindert, B. W. Bouter, Rutger H. T. Koornstra, F. J. Borm, C. H. Rikers, E. A. Kastelijn, B. M.J. Scholtes, Y. Klaver, E. J.M. Siemerink, D. M. van Diepen, A. L. Peerdeman, Mieke J. Aarts, K. H. Herbschleb, V. E.M. van den Boogaart, Karijn P M Suijkerbuijk, G. Douma, S. D. Bakker, Karlijn de Joode, A. J. Staal, M. P.L. Bard, J. A. Stigt, C. C.M. Pitz, L. J. C. van Warmerdam, E. Looysen, Laurens V. Beerepoot, P. Brocken, C. R. van Rooijen, N. J.M. Claessens, Haiko J. Bloemendal, A.J. van de Wouw, Astrid A M van der Veldt, E. Citgez, Franchette W P J van den Berkmortel, M. Youssef, E. J. Geraedts, Nico G.J. van Diemen, G. L. Veurink, E. J. Libourel, N. P. Barlo, Elisabeth G.E. de Vries, J.W.B. de Groot, Anne-Marie C. Dingemans, W. H. van Geffen, G. J.M. Herder, Pim G N J Mutsaers, L. Strobbe, Jolien Tol, R. Heller, L. M. Faber, B. Franken, Lizza E.L. Hendriks, Mathilde Jalving, O. C.J. Schuurbiers-Siebers, B. C.M. Haberkorn, M. A. Tiemessen, M. Slingerland

Publikováno v: European Journal of Cancer
European Journal of Cancer, 141, pp. 171-184
European Journal of Cancer, 141, 171-184
European Journal of Cancer, 141, 171-184. Elsevier Limited
European Journal of Cancer, 141, 171-184. ELSEVIER SCI LTD
European Journal of Cancer, 141, 171-184. Elsevier Ltd.

Aim of the study Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ab8641c47fce20aca6e3c9edc471009
http://www.scopus.com/inward/record.url?scp=85095410706&partnerID=8YFLogxK